Undisclosed CD3 TCB
/ CytomX, Astellas
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 16, 2026
In March 2026, Astellas chose to not advance the remaining preclinical research programs under the alliance resulting in a termination of the collaboration effective in the second quarter of 2026.
(GlobeNewswire)
Commercial • Oncology
April 03, 2024
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
(GlobeNewswire)
- "CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milestone payment to CytomX."
New molecule • Oncology
1 to 2
Of
2
Go to page
1